New ATHENA data suggest decrease in stroke risk with dronedarone for AF

210

More good news from the ATHENA trial, a double-blind, anti-arrhythmic, morbidity-mortality study that evaluated a new drug, dronedarone (Multaq, Sanofi-Aventis), in patients with atrial fibrillation. Results from a post-hoc analysis of the data from the trial show that dronedarone reduces stroke risk. The analysis was presented at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.